The MSA therapeutic market is gaining momentum through novel approaches targeting disease mechanisms, supported by orphan drug designations. Key innovators like Biohaven (verdiperstat), Theravance (TD-9855), and Modag (anle138b) are pioneering α-synuclein-targeting candidates in active clinical development, driving potential treatment breakthroughs for this progressive neurological disorder.
Download Market Analysis:
https://www.delveinsight.com/i....nfographics/multiple
Comment
Share
